- In antiviral cellular assays, antiviral potency (EC 90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 ...

(RTTNews) - Ascletis Pharma Inc. said Wednesday that the U.S. Food and Drug Administration has approved the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate ...

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a ...

(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) said China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate ...

Ascletis Pharma Inc., an innovative R&D driven biotech company, announces that its oral small molecule drug candidate ASC11, a 3-chymotrypsin like protease (3CLpro) inhibitor, demonstrated potential ...